Sökning: WFRF:(Mohorcic Katja)
> (2021) >
Selpercatinib in RE...
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN) : a retrospective analysis of patients treated through an access program
-
- Illini, Oliver (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.
-
- Hochmair, Maximilian Johannes (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria.
-
- Fabikan, Hannah (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.
-
visa fler...
-
- Weinlinger, Christoph (författare)
- Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria.
-
- Tufman, Amanda (författare)
- LMU Munchen, Klinikum Univ Muenchen, Med Klin & Poliklin, Mitglied Deutsch Zentrums Lungenforsch, CPC M, Munich, Bayern, Germany.
-
- Swalduz, Aurelie (författare)
- Ctr Leon Berard, Lyon, France.
-
- Lamberg, Kristina (författare)
- Uppsala universitet,Lung- allergi- och sömnforskning,Uppsala Univ Hosp, Sweden
-
- Hashemi, Sayed M. S. (författare)
- Vrije Univ Amsterdam, Med Ctr, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands.,Department of Pneumology, Ordensklinikum Elisabethinen Linz, Linz, Austria
-
- Huemer, Florian (författare)
- Ludwig Boltzmann Inst Lung Hlth, Dept Resp Care, Klin Penzing, Vienna, Austria.
-
- Vikström, Anders (författare)
- Linkoping Univ Hosp, Pulm clin, Linkoping, Sweden.,Region Östergötland, Lungmedicinska kliniken US
-
- Wermke, Martin (författare)
- Tech Univ Dresden, Med Fac C G Carus, NCT UCC Early Clin Trial, Unit Dresden, Dresden, Germany.
-
- Absenger, Gudrun (författare)
- Med Univ Graz, Dept Oncol, Graz, Austria.
-
- Addeo, Alfredo (författare)
- Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland.
-
- Banerji, Shantanu (författare)
- Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.
-
- Calles, Antonio (författare)
- Univ Gregorio Maranon, Hosp Gen, Med Oncol Dept, Madrid, Spain.
-
- Clarke, Stephen (författare)
- Royal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.
-
- Di Maio, Massimo (författare)
- Univ Turin, Dept Oncol, Turin, Italy.;Ordine Mauriziano Hosp, Med Oncol, Turin, Italy.
-
- Durand, Alice (författare)
- Univ Lyon, France Univ Claude Bernard Lyon 1, Hosp Civils Lyon, Canc Inst Lyon,Louis Pradel Hosp,Resp Dept, Lyon, France.
-
- Duruisseaux, Michael (författare)
- Hosp Civils Lyon, Canc Inst, Louis Pradel Hosp, Resp Dept, Lyon, France.;Canc Res Ctr Lyon, Oncopharmacol Lab, Lyon, France.;Univ Lyon, Univ Claude Bernard Lyon 1, Lyon, France.
-
- Itchins, Malinda (författare)
- Royal North Shore Hosp, Med Oncol Unit, St Leonards, NSW, Australia.
-
- Kääränien, Okko-Sakari (författare)
- Kuopio Univ Hosp, Ctr Canc, Kuopio, Finland.
-
- Krenn, Florian (författare)
- LKH Hochsteiermark Standort Leoben, Abt Lungenkrankheiten, Leoben, Austria.
-
- Laack, Eckart (författare)
- Studiengesellschaft Hamatoonkol Hamburg, Hamburg, Germany.
-
- de Langen, Adrianus Johannes (författare)
- Netherlands Canc Inst, Amsterdam, Netherlands.
-
- Mohorcic, Katja (författare)
- Univ Clin Goln, Med Oncol Unit, Golnik, Slovenia.
-
- Pall, Georg (författare)
- Univ Innsbruck Hosp, Dept Internal Med V Hematol Oncol, Innsbruck, Austria.
-
- Passaro, Antonio (författare)
- European Inst Oncol IRCCS, Div Thorac Oncol, Milan, Italy.
-
- Prager, Gerald (författare)
- Comprehens Canc Ctr Vienna, Dept Med I, Vienna, Austria.
-
- Rittmeyer, Achim (författare)
- LKI Lungenfachklin Immenhausen, Dept Thorac Oncol, Immenhausen, Germany.
-
- Rothenstein, Jeffrey (författare)
- R.S. McLaughlin Durham Regional Cancer Center at Lakeridge Health, Adjunct Assistant Professor Queen’s University, Ontario, Canada
-
Schumacher, Michael (författare)
-
- Woell, Ewald (författare)
- Department Internal Medicine, St. Vinzenz Krankenhaus Betriebs GmbH, Sanatoriumstr. 43, 6511 Zams, Austria
-
- Valipour, Arschang (författare)
- Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna
-
visa färre...
-
Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Floridsdorf, Brunner Str 68, A-1210 Vienna, Austria Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Vienna, Austria. (creator_code:org_t)
- 2021-06-11
- 2021
- Engelska.
-
Ingår i: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. - : Sage Publications. - 1758-8340 .- 1758-8359. ; 13
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://journals.sag...
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their efficacy in the real-world setting is unknown. Methods: A retrospective efficacy and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated in a selpercatinib access program (named patient protocol) between August 2019 and January 2021. Results: Data from 50 patients with RET fusion-positive advanced NSCLC treated with selpercatinib at 27 centers in 12 countries was analyzed. Most patients were Non-Asian (90%), female (60%), never-smokers (74%), with a median age of 65 years (range, 38-89). 32% of the patients had known brain metastasis at the time of selpercatinib treatment. Overall, 13 patients were treatment-naive, while 37 were pretreated with a median of three lines of therapy (range, 1-8). The objective response rate (ORR) was 68% [95% confidence interval (CI), 53-81] in the overall population. The disease control rate was 92%. The median progression-free survival was 15.6 months (95% CI, 8.8-22.4) after a median follow-up of 9 months. In patients with measurable brain metastases (n = 8) intracranial ORR reached 100%. In total, 88% of patients experienced treatment-related adverse events (TRAEs), a large majority of them being grade 1 or 2. The most common grade > 3 TRAEs were increased liver enzyme levels (in 10% of patients), prolonged QTc time (4%), abdominal pain (4%), hypertension (4%), and fatigue/asthenia (4%). None of patients discontinued selpercatinib treatment for safety reasons. No new safety concerns were observed, nor where there any treatment-related death. Conclusions: In this real-world setting, the selective RET-inhibitor selpercatinib demonstrated durable systemic and intracranial antitumor activity in RET fusion-positive NSCLC and was well tolerated.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- non-small cell lung cancer (NSCLC)
- real-world data
- RET gene fusions
- selpercatinib
- targeted therapy
- tyrosine kinase inhibitor (TKI)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Illini, Oliver
-
Hochmair, Maximi ...
-
Fabikan, Hannah
-
Weinlinger, Chri ...
-
Tufman, Amanda
-
Swalduz, Aurelie
-
visa fler...
-
Lamberg, Kristin ...
-
Hashemi, Sayed M ...
-
Huemer, Florian
-
Vikström, Anders
-
Wermke, Martin
-
Absenger, Gudrun
-
Addeo, Alfredo
-
Banerji, Shantan ...
-
Calles, Antonio
-
Clarke, Stephen
-
Di Maio, Massimo
-
Durand, Alice
-
Duruisseaux, Mic ...
-
Itchins, Malinda
-
Kääränien, Okko- ...
-
Krenn, Florian
-
Laack, Eckart
-
de Langen, Adria ...
-
Mohorcic, Katja
-
Pall, Georg
-
Passaro, Antonio
-
Prager, Gerald
-
Rittmeyer, Achim
-
Rothenstein, Jef ...
-
Schumacher, Mich ...
-
Woell, Ewald
-
Valipour, Arscha ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
THERAPEUTIC ADVA ...
- Av lärosätet
-
Uppsala universitet
-
Linköpings universitet